CLCS (Cell Source) Future 3-5Y EPS without NRI Growth Rate: N/A (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLCS Cell Source Inc CLCS
35 GF Score
Price $0.89
View Full Analysis

What is Cell Source Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Cell Source's Future 3-5Y EPS without NRI Growth Rate is N/A.

Cell Source  (OTCPK:CLCS) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Cell Source Future 3-5Y EPS without NRI Growth Rate Related Terms

CLCS vs EDSA, CTXR, ASBP: Future 3-5Y EPS without NRI Growth Rate Comparison

For the Biotechnology subindustry, Cell Source's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source Future 3-5Y EPS without NRI Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Cell Source's Future 3-5Y EPS without NRI Growth Rate falls into.


CLCS
35GF Score
Cell Source Inc CLCS
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.89
Price